#1 Clinical Trials Search in Europe

Cendakimab

Cendakimab is an innovative drug currently being studied in clinical trials for its potential therapeutic effects. These trials aim to evaluate the drug’s safety, effectiveness, and how it behaves in the human body. The studies involve both healthy volunteers and patients with specific conditions, providing valuable insights into Cendakimab’s potential as a treatment option.

Table of Contents

What is Cendakimab?

Cendakimab is a new drug currently being studied for its potential in treating certain medical conditions. It’s also known by several other names, including CC-93538, BMS-986355, and RPC4046[1][2][3]. These alternative names are often used in research settings or during the drug development process.

What Conditions Does Cendakimab Treat?

The primary condition that Cendakimab is being studied for is Eosinophilic Esophagitis (EoE)[3]. This is a chronic immune system disease where a type of white blood cell (called eosinophils) builds up in the lining of the tube that connects your mouth to your stomach (esophagus). This buildup, which is a reaction to foods, allergens or acid reflux, can inflame or injure the esophageal tissue, leading to difficulty swallowing or food getting stuck in the esophagus.

How is Cendakimab Administered?

Cendakimab is administered through subcutaneous injection. This means it’s injected just under the skin, rather than into a vein or muscle. The drug is being tested with different delivery methods:

  • Autoinjector: A device that automatically inserts the needle and delivers the drug when activated.
  • Prefilled syringe: A syringe that comes already filled with the correct dose of the medication[1].

Researchers are also studying how the drug levels in the body are affected when it’s injected at different sites on the body[1].

Current Clinical Trials

Cendakimab is currently undergoing several clinical trials to evaluate its effectiveness and safety. These trials include:

  1. A study comparing drug levels when administered via autoinjector versus prefilled syringe in healthy participants[1].
  2. A study evaluating the safety and tolerability of Cendakimab in healthy Chinese participants[2].
  3. A study investigating potential drug interactions in adults with active Eosinophilic Esophagitis[3].

These trials are helping researchers understand how the drug behaves in the body, its safety profile, and its potential effectiveness in treating Eosinophilic Esophagitis.

Safety and Side Effects

As Cendakimab is still in the clinical trial phase, its full safety profile is not yet established. However, the ongoing trials are closely monitoring for any potential side effects or safety concerns. Some of the aspects being evaluated include:

  • Treatment-emergent adverse events (TEAEs): These are any unfavorable and unintended sign, symptom, or disease that appears during the use of the drug, whether or not it’s considered related to the treatment[1][2][3].
  • Changes in clinical laboratory tests: This involves monitoring any abnormalities in blood tests or other laboratory examinations[1][2][3].
  • Changes in vital signs: This includes monitoring for any significant changes in blood pressure, heart rate, temperature, or respiratory rate[1][2][3].
  • Changes in physical examinations: This involves checking for any physical changes or abnormalities that may occur during treatment[1][2][3].
  • Changes in electrocardiograms (ECGs): This involves monitoring the electrical activity of the heart for any abnormalities[1][2][3].

Drug Interactions

One of the ongoing studies is specifically looking at potential drug interactions between Cendakimab and other medications[3]. This study is focusing on how Cendakimab might interact with drugs that are processed by certain liver enzymes called Cytochrome P450 (CYP). Understanding these interactions is crucial for ensuring the safe use of Cendakimab alongside other medications that patients might be taking.

Additionally, researchers are studying the immunogenicity of Cendakimab. This refers to the drug’s ability to provoke an immune response in the body, which is monitored by checking for the presence of anti-drug antibodies (ADAs) over time[3]. This information helps researchers understand how the body responds to the drug and whether this response could affect its effectiveness or safety.

Aspect Details
Drug Name Cendakimab (also known as CC-93538, BMS-986355, RPC4046)
Administration Method Subcutaneous injection
Study Populations Healthy volunteers, Chinese healthy participants, Eosinophilic Esophagitis patients
Primary Outcomes Drug concentration levels (Cmax, AUC)
Secondary Outcomes Safety assessments, tolerability, drug interactions
Key Study Objectives Evaluate pharmacokinetics, safety, tolerability, and potential drug interactions

FAQ

  • What is Cendakimab? Cendakimab is a new drug being studied in clinical trials. It's also known by other names such as CC-93538, BMS-986355, and RPC4046. The drug is being tested for its potential use in treating certain medical conditions.
  • What conditions is Cendakimab being studied for? Based on the available information, Cendakimab is being studied in healthy volunteers and in patients with Eosinophilic Esophagitis, a condition affecting the esophagus.
  • How is Cendakimab administered? Cendakimab is administered subcutaneously, which means it's injected under the skin. Some studies are comparing different methods of injection, such as using an autoinjector versus a prefilled syringe.
  • What are the main goals of these clinical trials? The main goals of these trials include evaluating the drug levels of Cendakimab in the body, assessing its safety and tolerability, and studying how it interacts with other substances in the body, particularly in patients with Eosinophilic Esophagitis.
  • Are there any known side effects of Cendakimab? The clinical trials are actively monitoring for potential side effects, which they refer to as adverse events. These may include changes in laboratory tests, vital signs, physical examinations, and electrocardiograms. However, specific side effects are not mentioned in the provided information.

Ongoing Clinical Trials on Cendakimab

  • Study on Long-Term Safety of Cendakimab for Adults and Adolescents with Eosinophilic Esophagitis

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Germany Italy Poland Portugal +1

Glossary

  • Subcutaneous: A method of administering medication by injecting it under the skin.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Cmax: The maximum concentration of a drug observed in the blood after administration.
  • AUC (Area Under the Curve): A measure of the total exposure to a drug over time, used to assess how much of the drug is in the body.
  • Half-life: The time it takes for the concentration of a drug in the body to reduce by half.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Eosinophilic Esophagitis: A chronic immune system disease characterized by a buildup of white blood cells (eosinophils) in the lining of the esophagus.
  • Cytochrome P450: A group of enzymes involved in drug metabolism in the body.
  • Drug-Drug Interaction: A situation in which one drug affects the activity of another when both are administered together.
  • Autoinjector: A medical device designed to deliver a single dose of a particular drug.
  • Prefilled Syringe: A syringe that comes pre-filled with a specific dose of medication.
  • Anti-Drug Antibodies (ADAs): Antibodies that the body produces against a therapeutic drug, which can potentially reduce the drug's effectiveness.

References

  1. https://clinicaltrials.gov/study/NCT05337345
  2. https://clinicaltrials.gov/study/NCT05638282
  3. https://clinicaltrials.gov/study/NCT05175352